Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients

Tumor Biology

Volumn 33, Issue 3, 2012, Pages 679-688

  Rousseau, Caroline ^a,b   Ferrer, Ludovic ^a,b   Supiot, Stéphane ^a,b   Bardiès, Manuel ^b   Davodeau, François ^b   Faivre Chauvet, Alain ^b,c   Baumgartner, Pierre ^a   Wijdenes, John ^d   Lacombe, Marie ^a   Barbet, Jacques ^b   Guillaume, Thierry ^c   Moreau, Philippe ^c   Harousseau, Jean Luc ^a,c   Kraeber Bodéré, Françoise ^a,b,c   Cherel, Michel ^a,b  

^a IRCNA   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d Diaclone   (France)

Author keywords

CD138; Dosimetry; Monoclonal antibody; Multiple myeloma; Radioimmunotherapy; Syndecan 1

Indexed keywords

D138 ANTIBODY; FLUORODEOXYGLUCOSE F 18; IODINE 131; MONOCLONAL ANTIBODY; SYNDECAN 1; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; RADIOACTIVE IODINE;

ABNORMAL LABORATORY RESULT; ADULT; ARTICLE; BLOOD; BLOOD TOXICITY; BONE MARROW; BONE MARROW TOXICITY; CASE REPORT; DISEASE SEVERITY; DOSIMETRY; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; FEASIBILITY STUDY; FEMALE; HUMAN; INFECTION; KIDNEY; LEUKOCYTE; LIVER; LIVER TOXICITY; MALE; MULTIPLE MYELOMA; NEPHROTOXICITY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIOIMMUNOTHERAPY; SIDE EFFECT; THROMBOCYTE; THROMBOCYTOPENIA; THYROID DISEASE; TREATMENT RESPONSE; URINE; WHOLE BODY CT; IMMUNOLOGY; MIDDLE AGED; RADIOMETRY; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOCONJUGATES; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; MULTIPLE MYELOMA; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOIMMUNOTHERAPY; RADIOMETRY; SYNDECAN-1; TREATMENT OUTCOME;

EID: 84863630150     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-012-0362-y     Document Type: Article

References (52)

1. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351(18):1860-73.
2. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3-9.
3. Facon T, Mary JY, Hulin C, Benboubker L, Attal M, Pegourie B, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370(9594):1209-18.
4. San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359(9):906-17.
5. Anderson KC. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions. Exp Hematol. 2007;35(4 Suppl 1):155-62.
6. Caers J, Van Valckenborgh E, Menu E, Van Camp B, Vanderkerken K. Unraveling the biology of multiple myeloma disease: cancer stem cells, acquired intracellular changes and interactions with the surrounding micro-environment. Bull Cancer. 2008;95(3):301-13.
7. Perez LE, Parquet N, Shain K, Nimmanapalli R, Alsina M, Anasetti C, et al. Bone marrow stroma confers resistance to Apo2 ligand/TRAIL inmultiplemyeloma in part by regulating c-FLIP. J Immunol. 2008;180(3):1545-55.
8. Sanderson RD, Yang Y. Syndecan-1: a dynamic regulator of the myeloma microenvironment. Clin ExpMetastasis. 2008;25(2):149-59.
9. Ridley RC, Xiao H, Hata H, Woodliff J, Epstein J, Sanderson RD. Expression of syndecan regulates human myeloma plasma cell adhesion to type I collagen. Blood. 1993;81(3):767-74.
10. Saunders S, Bernfield M. Cell surface proteoglycan binds mouse mammary epithelial cells to fibronectin and behaves as a receptor for interstitial matrix. J Cell Biol. 1988;106(2):423-30.
11. Jourdan M, Ferlin M, Legouffe E, Horvathova M, Liautard J, Rossi JF, et al. The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells. Br J Haematol. 1998;100(4):637-46.
12. Vooijs WC, Post J, Wijdenes J, Schuurman HJ, Bolognesi A, Polito L, et al. Efficacy and toxicity of plasma-cell-reactive monoclonal antibodies B-B2 and B-B4 and their immunotoxins. Cancer Immunol Immunother. 1996;42(6):319-28.
13. Jego G, Bataille R, Pellat-Deceunynck C. IL-6 is a growth factor for nonmalignant human plasmablasts. Blood. 2001;97:1817-22.
14. Matsui W, Huff CA, Wang Q, Malehorn MT, Barber J, Tanhehco Y, et al. Characterization of clonogenic multiple myeloma cells. Blood. 2004;103:2332-6.
15. Rasmussen T, Haaber J, Dahl IM, Knudsen LM, Kerndrup G, Lodahl M, et al. Identification of translocation products but not K-RASmutations in memory B cells from multiplemyeloma patients. Haematologica. 2010;95:1730-7.
16. Jakubikova J, Adamia S, Kost-Alimova M, Klippel S, Cervi D, Daley JF, et al. Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood. 2011;117:4409-19.
17. Chiron D, Surget S, Maïga S, Bataille R, Moreau P, Le Gouill S, et al. The peripheral CD138+ population but not the CD138-population contains myeloma clonogenic cells in plasma cell leukemia patients. Br J Haematol. 2011. doi:10.1111/j.1365-2141.2011.08904.x.
18. Seidel C, Sundan A, Hjorth M, Turesson I, Dahl IM, Abildgaard N, Waage A, Borset M. Serum syndecan-1: a new independent prognostic marker in multiple myeloma. Blood. 2000;95(2):388-92.
19. Bartlett AH, Hayashida K, Park PW. Molecular and cellular mechanisms of syndecans in tissue injury and inflammation. Mol Cells. 2007;24(2):153-66.
20. Yang Y, Yaccoby S, Liu W, Langford JK, Pumphrey CY, Theus A, Epstein J, Sanderson RD. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood. 2002;100(2):610-7.
21. Wijdenes J, Dore JM, Clement C, Vermot-Desroches C. CD138. J Biol Regul Homeost Agents. 2002;16(2):152-5.
22. Wijdenes J, Vooijs WC, Clement C, Post J, Morard F, Vita N, et al. A plasmocyte selective monoclonal antibody (B-B4) recognizes syndecan-1. Br J Haematol. 1996;94(2):318-23.
23. Govindan SV, Goldenberg DM. New antibody conjugates in cancer therapy. Scientific World J. 2010;10:2070-89.
24. Kraeber-Bodere F, Rousseau C, Bodet-Milin C, Ferrer L, Faivre-Chauvet A, Campion L, et al. Targeting, toxicity, and efficacy of 2-step, pretargeted radioimmunotherapy using a chimeric bispecific antibody and 131I-labeled bivalent hapten in a phase I optimization clinical trial. J Nucl Med. 2006;47(2):247-55.
25. Williams T, Kelley C. gnuplot 4.2.6. (2009) Available from URL: http://www.gnuplot.info. Accessed 18 Feb. 2009.
26. Ogawa K, Harata Y, Ichihara T, Kubo A, Hashimoto S. A practical method for position-dependent Compton-scatter correction in single photon emission CT. IEEE Trans Med Imaging. 1991;10(3):408-12.
27. Buvat I, Benali H, Frouin F, Bazin JP, Di Paola R. Target apexseeking in factor analysis of medical image sequences. Phys Med Biol. 1993;38(1):123-38.
28. Yushkevich PA, Piven J, Hazlett HC, Smith RG, Ho S, Gee JC, et al. User-guided 3D active contour segmentation of anatomical structures: significantly improved efficiency and reliability. Neuroimage. 2006;31(3):1116-28.
29. Ferrer L, Kraeber-Bodere F, Bodet-Milin C, Rousseau C, Le Gouill S, Wegener WA, et al. Three methods assessing red marrow dosimetry in lymphoma patients treated with radioimmunotherapy. Cancer. 2010;116(4 Suppl):1093-100.
30. Stabin MG, Siegel JA. Physical models and dose factors for use in internal dose assessment. Health Phys. 2003;85(3):294-310.
31. Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40(2):37S-61S.
32. Bartel TB, Haessler J, Brown TL, Shaughnessy Jr JD, van Rhee F, Anaissie E, et al. F18-fluorodeoxyglucose positron emission tomography in the context of other imaging techniques and prognostic factors in multiple myeloma. Blood. 2009;114:2068-76.
33. Zamagni E, Nanni C, Patriarca F, Englaro E, Castellucci P, Geatti O, et al. A prospective comparison of 18F-fluorodeoxyglucose positron emission tomography-computed tomography, magnetic resonance imaging and whole-body planar radiographs in the assessment of bone disease in newly diagnosed multiple myeloma. Haematologica. 2007;92:50-5.
34. McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med. 1998;25(9):1341-51.
35. Couturier O, Faivre-Chauvet A, Filippovich IV, Thedrez P, Sai-Maurel C, Bardies M, et al. Validation of 213Bi-alpha radioimmunotherapy for multiple myeloma. Clin Cancer Res. 1999;5(10 Suppl):3165s-70s.
36. Supiot S, Faivre-Chauvet A, Couturier O, Heymann MF, Robillard N, Kraeber-Bodere F, et al. Comparison of the biologic effects of MA5 and B-B4 monoclonal antibody labeled with iodine-131 and bismuth-213 on multiple myeloma. Cancer. 2002;94(4 Suppl):1202-9.
37. Cherel M, Gouard S, Gaignerie A, Gaschet J, Bigot-Corbel E, Faivre-Chauvet A, et al. Targeting the CD138 antigen for the treatment of multiple myeloma with Bismuth-213. Eur J Nucl Med Mol Imaging. 2009;36 Suppl 2:S194-233. abstract.
38. Liersch T, Meller J, Kulle B, Behr TM, Markus P, Langer C, et al. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol. 2005;23:6763-70.
39. Devys A, Thedrez P, Gautherot E, Faivre-Chauvet A, Sai-Maurel C, Rouvier E, et al. Comparative targeting of human coloncarcinoma multicell spheroids using one-and two-step (bispecific antibody) techniques. Int J Cancer. 1996;67:883-91.
40. Mirallie E, Vuillez JP, Bardet S, Frampas E, Dupas B, Ferrer L, et al. High frequency of bone/bone marrow involvement in advanced medullary thyroid cancer. J Clin Endocrinol Metab. 2005;90:779-88.
41. Tassone P, Goldmacher VS, Neri P, Gozzini A, Shammas MA, Whiteman KR, et al. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood. 2004;104(12):3688-96.
42. Vanderkerken K, De Raeve H, Goes E, Van Meirvenne S, Radl J, Van Riet I, Thielemans K, Van Camp B. Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse. Br J Cancer. 1997;76(4):451-60.
43. Sjögreen-Gleisner K, Dewaraja YK, Chiesa C, Tennvall J, Lindén O, Strand SE, Ljungberg M. Dosimetry in patients with B-cell lymphoma treated with [(90) Y]ibritumomab tiuxetan or [(131) I]tositumomab. Q J Nucl Med Mol Imaging. 2011;55(2):126-54.
44. Meredith RF, Shen S, Forero A, Lo Buglio A. A method to correct for radioactivity in large vessels that overlap the spine in imagingbasedmarrow dosimetry of lumbar vertebrae. J Nucl Med. 2008;49(2):279-84.
45. Juweid M, Sharkey RM, Siegel JA, Behr T, Goldenberg DM. Estimates of red marrow dose by sacral scintigraphy in radioimmunotherapy patients having non-Hodgkin's lymphoma and diffuse bone marrow uptake. Cancer Res. 1995;55(23 Suppl):5827s-31s.
46. Siegel JA. Establishing a clinically meaningful predictive model of hematologic toxicity in nonmyeloablative targeted radiotherapy: practical aspects and limitations of red marrow dosimetry. Cancer Biother Radiopharm. 2005;20:126-40.
47. De Nardo DA, De Nardo GL, O'Donnell RT, et al. Imaging for improved prediction of myelotoxicity after radioimmunotherapy. Cancer. 1997;80:2558s-66s.
48. Sgouros G, Stabin M, Erdi Y, et al. Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components. Med Phys. 2000;27:2150-64.
49. Research Triangle Park, NC: GlaxoSmithKline. Bexxar prescribing information [package insert]. 2005. Available at: http://us.gsk.com/products/ assets/us-bexxar.pdf
50. Chatterjee M, Chakraborty T, Tassone P. Multiple myeloma: monoclonal antibodies-based immunotherapeutic strategies and targeted radiotherapy. Eur J Cancer. 2006;42(11):1640-52.
51. Zalutsky MR, Bigner DD. Radioimmunotherapy with alpha-particle emitting radioimmunoconjugates. Acta Oncol. 1996;35(3):373-9.
52. Couturier O, Supiot S, Degraef-Mougin M, Faivre-Chauvet A, Carlier T, Chatal JF, et al. Cancer radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med Mol Imaging. 2005;32(5):601-6s14.